Skip to content

Effects of Upgrading From Right Ventricular Pacing to Cardiac Resynchronization Therapy and Comparison With Dual-Chamber Defibrillator

Effects of Upgrading From Right Ventricular Pacing to Cardiac Resynchronization Therapy and Comparison With Dual-Chamber Defibrillator

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07077928
Enrollment
307
Registered
2025-07-22
Start date
2019-01-01
Completion date
2023-12-31
Last updated
2025-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure, Ventricular Arrhythmias and Cardiac Arrest

Keywords

Heart failure, Cardiac Resynchronization Therapy, Upgrade, Defibrillator, Pacemaker

Brief summary

Patients who consecutively underwent de novo CRT implantation, CRT upgrade, and DDDR ICD implantation at the Cardiology Clinic of Bursa Postgraduate Hospital between January 2019 and December 2023 according to the European Society of Cardiology (ESC) guideline criteria were included in the study.

Detailed description

100 patients receiving de-novo CRT, 38 patients upgrading from RV pacing to CRT, and 169 patients receiving a DDDR-ICD implantation were included the study. Inclusion criteria were left ventricular ejection fraction lower than 35% and either QRS longer than 130ms for CRT groups or QRS≤120ms for the DDDR-ICD group. Primary endpoints were all-cause mortality and hospitalization for heart failure during a follow-up period extending up to 5 years.

Interventions

DEVICEPacemaker upgrade

CRT upgrade

Sponsors

Bursa Postgraduate Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

De novo CRT group: * Sinus rhythm, * age higher than 18, * EF lower than 35%, * New York Heart Association (NYHA) class II-IV, * QRS \>130 ms, * patients with atrial fibrillation (AF) who converted to sinus rhythm and who remained symptomatic despite 3-6 months of guideline-directed medical therapy. CRT upgrade group: * Sinus rhythm, * age higher than 18, * EF lower than 35%, * NYHA class II-IV, * QRS duration \>130 ms with RV pacing, -\> 20% RV pacing rate, * patients with AF who converted to sinus rhythm, at least 6 months since pacemaker implantation, and symptomatic despite 3-6 months of guideline directed medical therapy. DDDR ICD group: * Sinus rhythm, * age higher than 18, * EF lower than 35%, * QRS ≤120 ms, * NYHA class II-IV, * patients with AF converted to sinus rhythm, * receiving guideline-directed medical therapy.

Exclusion criteria

* patients with atrial fibrillation * LV EF higher than 50 % * NYHA Class 1 * Patients with active infection or cancer

Design outcomes

Primary

MeasureTime frame
All cause mortality and hospitalization for heart failure24 months

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026